Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study

被引：11

作者：

Marouf, Amira ^{[1
,2
,3
]}

Cottereau, Anne Segolene ^{[2
,4
]}

Kanoun, Salim ^{[5
]}

Deschamps, Paul ^{[1
,2
]}

Meignan, Michel ^{[6
,7
]}

Franchi, Patricia ^{[1
,2
]}

Sibon, David ^{[8
,9
]}

Antoine, Clara ^{[6
]}

Gastinne, Thomas ^{[10
]}

Borel, Cecile ^{[11
]}

Hammoud, Mohammad ^{[12
]}

Sicard, Guillaume ^{[13
]}

Gille, Romane ^{[14
]}

Cavalieri, Doriane ^{[15
]}

Stamatoullas, Aspasia ^{[16
]}

Filliatre-Clement, Lauriane ^{[16
]}

Lazarovici, Julien ^{[17
]}

Chauchet, Adrien ^{[18
]}

Fornecker, Luc-Matthieu ^{[19
,20
,21
]}

Amorin, Sandy ^{[22
]}

Rocquet, Mathieu ^{[1
]}

Raus, Nicole ^{[23
,24
]}

Burroni, Barbara ^{[25
,26
]}

Rubio, Marie Therese ^{[24
,27
,28
]}

Bouscary, Didier ^{[1
,2
,29
]}

Quittet, Philippe ^{[30
]}

Casasnovas, Rene Olivier ^{[31
,32
]}

Brice, Pauline ^{[33
]}

Ghesquieres, Herve ^{[34
]}

Tamburini, Jerome ^{[1
,2
,29
,35
]}

Deau, Benedicte ^{[1
,2
]}

机构：

[1] Hop Cochin, AP HP, Dept Hematol, Paris, France

[2] Univ Paris, Paris, France

[3] INSERM, UMR 1163, Inst Imagine, Paris, France

[4] Hop Cochin, AP HP, Dept Nucl Med, Paris, France

[5] INSERM, Canc Res Ctr Toulouse CRCT, Team 9, UMR 1037, Toulouse, France

[6] Hop Henri Mondor, Lymphoma Study Assoc Imaging, Lymphoma Acad Res Org LYSARC, Creteil, France

[7] Paris Est Univ, Creteil, France

[8] Necker Univ Hosp, Hematol Dept, AP HP, Paris, France

[9] Necker Univ Hosp, Inst Necker Enfants Malades, AP HP, INSERM U1151, Paris, France

[10] Nantes Univ Hosp, Dept Hematol, Nantes, France

[11] Inst Univ Canc Toulouse Oncopole, Dept Hematol, Toulouse, France

[12] Hop Henri Mondor, Lymphoid Malignancies Unit, Creteil, France

[13] Aix Marseille Univ, Dept Hematol, Marseille, France

[14] Ctr Leon Berard, Dept Med Oncol, Lyon, France

[15] Ctr Hosp Univ CHU Estaing, Dept Hematol, Clermont Ferrand, France

[16] Clin Louis Pasteur, Dept Hematol, Nancy, France

[17] Inst Gustave Roussy, Dept Hematol, Villejuif, France

[18] CHU Besancon, Dept Hematol, Besancon, France

[19] Strasbourg Univ Hosp, Strasbourg, France

[20] INSERM S 1113, Strasbourg, France

[21] Strasbourg Univ, Fac Med, Strasbourg, France

[22] Hop St Vincent de Paul, Dept Hematol, Lille, France

[23] Hop Lyon Sud, Dept Hematol, Pierre Benite, France

[24] Soc Francophone Greffe Moelle & Therapie Cellulai, Pierre Benite, France

[25] Hop Cochin, AP HP, Serv Pathol, Paris, France

[26] Paris Univ, Sorbonne Univ, INSERM, Ctr Rech Cordeliers, Paris, France

[27] Hop Brabois, CHRU Nancy, Dept Hematol, Nancy, France

[28] Biopole Univ Lorraine, CNRS UMR 7365, Equipe 6, Vandoeuvre Les Nancy, France

[29] INSERM, Inst Cochin, U1016, Paris, France

[30] Univ Montpellier, Dept Hematol, Montpellier, France

[31] Dijon Univ Hosp, Dept Hematol, Dijon, France

[32] CHU Dijon, INSERM UMR 1231, Dijon, France

[33] Hop St Louis, CHU Paris GH St Louis Lariboisiere F Widal, Dept Hematol, Paris, France

[34] Ctr Hosp Lyon Sud, Dept Hematol, Pierre Benite, France

[35] Univ Geneva, Fac Med, Translat Res Ctr Oncohematol, Geneva 4, Switzerland

来源：

HAEMATOLOGICA | 2022年 / 107卷 / 07期

关键词：

THERAPY; COMBINATION; 2ND-LINE;

D O I：

10.3324/haematol.2021.279564

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1681 / 1686

页数：6

共 14 条

[1] PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation
Armand, Philippe
Chen, Yi-Bin
Redd, Robert A.
Joyce, Robin M.
Bsat, Jad
Jeter, Erin
Merryman, Reid W.
Coleman, Kimberly C.
Dahi, Parastoo B.
Nieto, Yago
LaCasce, Ann S.
Fisher, David C.
Ng, Samuel Y.
Odejide, Oreofe O.
Freedman, Arnold S.
Kim, Austin, I
Crombie, Jennifer L.
Jacobson, Caron A.
Jacobsen, Eric D.
Wong, Jeffrey L.
Patel, Sanjay S.
Ritz, Jerome
Rodig, Scott J.
Shipp, Margaret A.
Herrera, Alex F.
[J]. BLOOD, 2019, 134 (01) : 22 - 29
[2] Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
Garcia-Sanz, R.
Sureda, A.
de la Cruz, F.
Canales, M.
Gonzalez, A. P.
Pinana, J. L.
Rodriguez, A.
Gutierrez, A.
Domingo-Domenech, E.
Sanchez-Gonzalez, B.
Rodriguez, G.
Lopez, J.
Moreno, M.
Rodriguez-Salazar, M. J.
Jimenez-Cabrera, S.
Caballero, M. D.
Martinez, C.
[J]. ANNALS OF ONCOLOGY, 2019, 30 (04) : 612 - 620
[3] Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
Herrera, Alex F.
Moskowitz, Alison J.
Bartlett, Nancy L.
Vose, Julie M.
Ramchandren, Radhakrishnan
Feldman, Tatyana A.
LaCasce, Ann S.
Ansell, Stephen M.
Moskowitz, Craig H.
Fenton, Keenan
Ogden, Carol Anne
Taft, David
Zhang, Qu
Kato, Kazunobu
Campbell, Mary
Advani, Ranjana H.
[J]. BLOOD, 2018, 131 (11) : 1183 - 1194
[4] Hodgkin Lymphoma, Version 2.2020
Hoppe, Richard T.
Advani, Ranjana H.
Ai, Weiyun Z.
Ambinder, Richard F.
Armand, Philippe
Bello, Celeste M.
Benitez, Cecil M.
Bierman, Philip J.
Boughan, Kirsten M.
Dabaja, Bouthaina
Gordon, Leo, I
Hernandez-Ilizaliturri, Francisco J.
Herrera, Alex F.
Hochberg, Ephraim P.
Huang, Jiayi
Johnston, Patrick B.
Kaminski, Mark S.
Kenkre, Vaishalee P.
Khan, Nadia
Lynch, Ryan C.
Maddocks, Kami
McConathy, Jonathan
McKinney, Matthew
Metzger, Monika
Morgan, David
Mulroney, Carolyn
Rabinovitch, Rachel
Rosenspire, Karen C.
Seropian, Stuart
Tao, Randa
Winter, Jane N.
Yahalom, Joachim
Burns, Jennifer L.
Ogba, Ndiya
[J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (06): : 755 - 781
[5] Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study
Kersten, Marie Jose
Driessen, Julia
Zijlstra, Josee M.
Plattel, Wouter J.
Morschhauser, Franck
Lugtenburg, Pieternella J.
Brice, Pauline
Hutchings, Martin
Gastinne, Thomas
Liu, Roberto
Burggraaff, Coreline N.
Nijland, Marcel
Tonino, Sanne H.
Arens, Anne I. J.
Valkema, Roelf
van Tinteren, Harm
Lopez-Yurda, Marta
Diepstra, Arjan
De Jong, Daphne
Hagenbeek, Anton
[J]. HAEMATOLOGICA, 2021, 106 (04) : 1129 - 1129
[6] Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
LaCasce, Ann S.
Bociek, R. Gregory
Sawas, Ahmed
Caimi, Paolo
Agura, Edward
Matous, Jeffrey
Ansell, Stephen M.
Crosswell, Howland E.
Islas-Ohlmayer, Miguel
Behler, Caroline
Cheung, Eric
Forero-Torres, Andres
Vose, Julie
O'Connor, Owen A.
Josephson, Neil
Wang, Yinghui
Advani, Ranjana
[J]. BLOOD, 2018, 132 (01) : 40 - 48
[7] Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma
Michallet, Anne-Sophie
Guillermin, Yann
Deau, Benedicte
Lebras, Laure
Harel, Stephanie
Amorin, Sandy
Reynes, Claire
Salles, Gilles
Subtil, Fabien
Brice, Pauline
[J]. HAEMATOLOGICA, 2015, 100 (07) : E269 - E271
[8] Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
Moskowitz, Alison J.
Shah, Gunjan
Schoeder, Heiko
Ganesan, Nivetha
Drill, Esther
Hancock, Helen
Davey, Theresa
Perez, Leslie
Ryu, Sunyoung
Sohail, Samia
Santarosa, Alayna
Galasso, Natasha
Neuman, Rachel
Liotta, Brielle
Blouin, William
Kumar, Anita
Lahoud, Oscar
Batlevi, Connie L.
Hamlin, Paul
Straus, David J.
Rodriguez-Rivera, Ildefonso
Owens, Colette
Caron, Philip
Intlekofer, Andrew M.
Hamilton, Audrey
Horwitz, Steven M.
Falchi, Lorenzo
Joffe, Erel
Johnson, William
Lee, Christina
Palomba, M. Lia
Noy, Ariela
Matasar, Matthew J.
Pongas, Georgios
Salles, Gilles
Vardhana, Santosha
Sanin, Beatriz Wills
von Keudell, Gottfried
Yahalom, Joachim
Dogan, Ahmet
Zelenetz, Andrew D.
Moskowitz, Craig H.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28) : 3109 - +
[9] Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
Moskowitz, Alison J.
Schoder, Heiko
Gavane, Somali
Thoren, Katie L.
Fleisher, Martin
Yahalom, Joachim
McCall, Susan J.
Cadzin, Briana R.
Fox, Stephanie Y.
Gerecitano, John
Grewal, Ravinder
Hamlin, Paul A.
Horwitz, Steven M.
Kumar, Anita
Matasar, Matthew
Ni, Andy
Noy, Ariela
Palomba, M. Lia
Perales, Miguel-Angel
Portlock, Carol S.
Sauter, Craig
Straus, David
Younes, Anas
Zelenetz, Andrew D.
Moskowitz, Craig H.
[J]. BLOOD, 2017, 130 (20) : 2196 - 2203
[10] PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study
Moskowitz, Alison J.
Schoeder, Heiko
Yahalom, Joachim
McCall, Susan J.
Fox, Stephanie Y.
Gerecitano, John
Grewal, Ravinder
Hamlin, Paul A.
Horwitz, Steven
Kobos, Rachel
Kumar, Anita
Matasar, Matthew
Noy, Ariela
Palomba, M. Lia
Perales, Miguel-Angel
Portlock, Carol S.
Sauter, Craig
Shukla, Neerav
Steinherz, Peter
Straus, David
Trippett, Tanya
Younes, Anas
Zelenetz, Andrew
Moskowitz, Craig H.
[J]. LANCET ONCOLOGY, 2015, 16 (03) : 284 - 292

← 1 2 →